UM CFAR SCCC Argentina Consortium for research and training in Virally Induced AIDS Malignancies

大约80%的病毒性癌症发生在LMICs等新兴经济体国家。一个重要的子集 大多数由病毒引起的恶性肿瘤是在艾滋病毒/艾滋病(艾滋病相关恶性肿瘤/AM)的背景下发生的。拉丁语 美国由病毒(包括HR-HPV、EBV、 这往往会不成比例地影响弱势群体和社会弱势群体。海流 该联盟致力于发展艾滋病相关恶性肿瘤的研究力量，同时 发展一大批独立的基础、转化性和临床艾滋病-恶性肿瘤研究人员 阿根廷。目前的U54将专注于初级科学家的职业发展，属于现有的 UM CFAR与阿根廷实验室的联盟通过开发专注于 《病毒学基础、翻译和临床研究与培训网络》的总主题和癌症类型- 诱发的艾滋病定义的恶性肿瘤不成比例地影响到艾滋病毒/艾滋病风险最高的阿根廷人群 爱滋病“。在布宜诺斯艾利斯的情况下，这既是艾滋病毒感染率为11%的男男性接触者群体，也是 变性人妇女(TGW)人群，艾滋病毒感染率为37%，也是最高的 感染肿瘤病毒KSHV和HR-HPV的风险，以及发展KS和肛门癌的风险。会的 进一步发展该联盟目前高度互补和综合的研究成果 由高度定制的职业提升和共享资源核心支持的项目将利用 艾滋病毒/艾滋病和病毒肿瘤学研究的杰出研究、人力资源和基础设施 在密歇根大学的CFAR、西尔维斯特癌症中心、阿根廷机构和阿根廷美国强大的网络中 与该联盟有关联的美国科学家。它的组成部分将包括行政核心、职业 增强核心、共享资源核心和三个指导研究项目，将利用和 增强网络的科学和临床能力，生成并利用临床信息库 样本和纵向队列，这将使临床结果与分子/基因数据相关联。 目标1：通过发展一大批初级研究人员的职业生涯来发展AM的研究能力 联盟机构提供的共享资源和科学网络的背景。目标2： 关于“病毒引起的艾滋病定义的恶性肿瘤不成比例地影响阿根廷人群的研究” 《艾滋病毒/艾滋病的最高风险》阐明肿瘤发生的分子和细胞机制，确定 治疗靶点，预防癌症，方便诊断和治疗。P1：中国的致癌信号网络 将艾滋病相关病毒癌症作为化学预防和治疗的目标。P2：分子、病毒和遗传 影响阿根廷艾滋病毒高风险人群的病毒诱导的艾滋病定义癌症的流行病学 感染。P3：确定凝集素-葡聚糖相互作用在病毒诱导的艾滋病相关癌症中的作用。

Around 80% of viral cancers occur in countries with emerging economies such as LMICs. An important subset of virally induced malignancies occurs in the context of HIV/ AIDS (AIDS associated Malignancies/ AM). Latin America have a high prevalence of AIDS-associated Malignancies caused by viruses (including HR-HPV, EBV, KSHV) which tend to disproportionally affect underprivileged and socially vulnerable populations. The current consortium addresses the need of developing research strength in AIDS associated Malignancies while developing a critical mass of independent basic, translational and clinical AIDS-malignancies researchers of Argentina. The current U54 will focus in the career development of junior scientists belonging to an existing consortium of UM CFAR with Argentina Labs through the development of mentored research focusing in the general theme and cancer type of “Basic, translational and Clinical research and training network in virally- induced AIDS-defining malignancies disproportionally affecting Argentina populations with highest risk of HIV/ AIDS”. In the case of Buenos Aires this is both the MSM population with a 11% HIV-infection incidence and the transgender women (TGW) population with an HIV-infection incidence of 37% which are at also the highest risk for infection with oncoviruses KSHV and HR-HPV, and to develop KS and anogenital carcinoma. It will further develop areas emerging from highly complementary and integrated current research of the consortium projects supported by highly tailored Career Enhancement and Shared Resources Cores that will leverage the outstanding research, human resources and infrastructure for HIV/AIDS and viral oncology research available at UM's CFAR, Sylvester Cancer Center, Argentina institutions and the powerful network of Argentine US scientists in USA associated with the consortium. Its components will include an Administrative core, a career enhancement core, a shared resource core and three projects of mentored research that will leverage and enhance the scientific and clinical capacity of the network, generating and leveraging a repository of clinical samples and longitudinal cohort that will enable to correlate clinical findings with molecular/genetic data. Aim 1: To develop research capacity in AM by developing the career of a critical mass of junior researchers in the context of shared resources and scientific networks provided by the consortium institutions. Aim 2: research on “Viral induced AIDS-defining malignancies disproportionally affecting populations in Argentina with the highest risk of HIV/ AIDS” to elucidate molecular and cellular mechanisms of oncogenesis, identify therapeutic targets, prevent cancer, facilitate diagnosis and treatment. P1: Oncogenic signaling networks in AIDS-associated viral cancers as targets of chemoprevention and treatment. P2: Molecular, viral and genetic epidemiology of virally induced AIDS-defining cancers affecting Argentina population with highest risk for HIV infection. P3: Defining the role of lectin-glycan interactions in virally induced AIDS-associated cancers.